Could a simple progesterone shot replace standard IVF drugs?
NCT ID NCT07350317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial will compare a daily shot of natural progesterone (Prolutex) against the standard drug cetrorelix for preventing early ovulation in women undergoing freeze-all IVF. About 230 women aged 18-40 will be enrolled. The goal is to see if progesterone works just as well, potentially offering a simpler and cheaper option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
subcutaneous natural progesterone (Prolutex)
What this could lead to
If successful, this could offer a simpler, more cost-effective alternative to current medications for preventing early ovulation during IVF.
What could go wrong
This is an early-stage comparison of two approved drugs, so the new use may not prove as effective. The trial is small (230 participants) and not yet recruiting, so results are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASSISTED REPRODUCTIVE TECHNIQUES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••